Literature DB >> 6796129

Human factor VIII procoagulant activity and phospholipid interaction.

A Lajmanovich, G Hudry-Clergeon, J M Freyssinet, G Marguerie.   

Abstract

The interaction between purified human factor VIII and phospholipid vesicles was investigated. The binding of factor VIII to an equimolecular mixture of phosphatidylserine (PS) and phosphatidylcholine (PC) was studied by sucrose gradient ultracentrifugation (10-40% w/v saccharose in 0.01 M Tris-HC1/0.15 M NaCl buffer (pH 7). In the absence of phospholipids all factor VIII activities (VIII R : WF and VIII R : AG) were found in the zone of highest sucrose density including the factor VIII related protein subunit (200 000 molecular weight). In the presence of an equimolecular mixture of PS/PC VIII R : WF activity, VIII R: AG and factor VIII related protein still migrated to the bottom of the tube, while VIII: C activity remained at the top where phospholipids were found. Thus a dissociation phenomenon between VIII : C and the other factor VIII related activities was apparent in the presence of phospholipids. These results also demonstrate the binding of factor VIII: C to certain active phospholipids.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6796129     DOI: 10.1016/0304-4165(81)90056-8

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  13 in total

Review 1.  Insight into the structure, function, and biosynthesis of factor VIII through recombinant DNA technology.

Authors:  R J Kaufman
Journal:  Ann Hematol       Date:  1991-09       Impact factor: 3.673

2.  Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid.

Authors:  M Arai; D Scandella; L W Hoyer
Journal:  J Clin Invest       Date:  1989-06       Impact factor: 14.808

3.  Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies.

Authors:  Justin D Walter; Rachel A Werther; Maria S Polozova; Julie Pohlman; John F Healey; Shannon L Meeks; Pete Lollar; P Clint Spiegel
Journal:  J Biol Chem       Date:  2013-02-15       Impact factor: 5.157

4.  Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry.

Authors:  A M Sevy; J F Healey; W Deng; P C Spiegel; S L Meeks; R Li
Journal:  J Thromb Haemost       Date:  2013-12       Impact factor: 5.824

5.  Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model.

Authors:  S L Meeks; J F Healey; E T Parker; R T Barrow; P Lollar
Journal:  J Thromb Haemost       Date:  2009-01-24       Impact factor: 5.824

Review 6.  B-cell and T-cell epitopes in anti-factor VIII immune responses.

Authors:  Kathleen P Pratt; Arthur R Thompson
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

7.  The diversity of the immune response to the A2 domain of human factor VIII.

Authors:  Rebecca C Markovitz; John F Healey; Ernest T Parker; Shannon L Meeks; Pete Lollar
Journal:  Blood       Date:  2013-01-24       Impact factor: 22.113

8.  Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors.

Authors:  Shannon L Meeks; John F Healey; Ernest T Parker; Rachel T Barrow; Pete Lollar
Journal:  Blood       Date:  2008-05-21       Impact factor: 22.113

9.  Binding of human blood-coagulation Factors IXa and X to phospholipid membranes.

Authors:  K Mertens; R Cupers; A Van Wijngaarden; R M Bertina
Journal:  Biochem J       Date:  1984-11-01       Impact factor: 3.857

10.  The association of human coagulation factors VIII, IXa and X with phospholipid vesicles involves both electrostatic and hydrophobic interactions.

Authors:  J S Atkins; P R Ganz
Journal:  Mol Cell Biochem       Date:  1992-05-13       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.